Hormone therapy for breast cancer is a treatment for breast cancers that are sensitive to hormones. The most common forms of hormone therapy for breast cancer work by blocking hormones from attaching to cancer cells or by decreasing your body's production of hormones.
Hormone therapy for breast cancer is often used after surgery to reduce the risk that the cancer will return. Hormone therapy for breast cancer may also be used to shrink a tumor before an operation, making it more likely the cancer will be removed completely.
If your cancer has spread to other parts of your body, hormone therapy for breast cancer may help control it.
Hormone therapy for breast cancer is only used to treat cancers that are hormone sensitive.
Some breast cancers are fueled by the natural hormones estrogen and progesterone. Doctors refer to these cancers as estrogen receptor positive (ER positive) or progesterone receptor positive (PR positive).
Your doctor determines if your cancer is ER positive or PR positive by analyzing a sample of your cancer cells.
Hormone therapy for breast cancer can help to:
- Prevent cancer from coming back
- Decrease the risk of cancer developing in other breast tissue
- Slow or stop the growth of cancer that has spread
- Reduce the size of a tumor prior to surgery
Side effects of hormone therapy for breast cancer include:
- Hot flashes
- Vaginal discharge
- Vaginal dryness or irritation
- Joint and muscle pain
- Impotence in men with breast cancer
Less common, more-serious side effects of hormone therapy may include:
- Blood clots in veins
- Endometrial cancer or uterine cancer
- Heart disease
There are several approaches to hormone therapy.
Medications that block hormones from attaching to cancer cells
One approach to hormone therapy is to stop the hormones from attaching to the cancer cells. When the hormones can't access the cancer cells, the tumor growth may slow and the cells may die.
Breast cancer medications that have this action include:
Tamoxifen. Tamoxifen is usually taken daily in pill form. It's used to reduce the risk of cancer recurrence in women who have been treated for early-stage breast cancer. In this situation, it's typically taken for five to 10 years.
Tamoxifen may also be used to treat cancer in women with advanced cancer. Tamoxifen is appropriate for both premenopausal women and postmenopausal women.
- Toremifene (Fareston). Toremifene is taken as a daily pill. It's used to treat breast cancer that has spread to other areas of the body. Toremifene is approved for use in postmenopausal women.
- Fulvestrant (Faslodex). Fulvestrant is administered as a shot every two weeks. It's used in postmenopausal women to treat advanced breast cancer in situations where other hormone therapies are no longer working.
Medications that stop the body from making estrogen after menopause
Aromatase inhibitors are a class of medicines that reduce the amount of estrogen in your body, depriving breast cancer cells of the hormones they need to grow and thrive.
Aromatase inhibitors are used in women who have undergone menopause.
Aromatase inhibitors used to treat breast cancer include:
- Anastrozole (Arimidex). Anastrozole is used to reduce the risk of cancer recurrence in women who have been treated for early-stage breast cancer. It can also be used to treat advanced breast cancer.
- Exemestane (Aromasin). Exemestane is used to reduce the risk of cancer recurrence in women who have been treated for early-stage breast cancer. It's sometimes used after taking tamoxifen for two or three years. It can also be used to treat advanced breast cancer in women for whom tamoxifen is no longer working.
- Letrozole (Femara). Letrozole is used to reduce the risk of cancer recurrence in women who have been treated for early-stage breast cancer. It can be used alone or given after completing tamoxifen treatment. Letrozole is also used to treat advanced breast cancer.
Aromatase inhibitors are given as pills you take once a day. How long you continue aromatase inhibitors depends on your specific situation.
Treatments to stop ovarian function in premenopausal women
Women who haven't undergone menopause — either naturally or as a result of cancer treatment — may opt to undergo treatment to stop their ovaries from producing hormones. These strategies are generally used in women with advanced breast cancer.
Options may include:
- Surgery to remove the ovaries (oophorectomy)
- Radiation therapy aimed at the ovaries
- Treatment with goserelin (Zoladex)
Treatments to stop ovarian function may allow premenopausal women to take medications only available to postmenopausal women.
You'll meet with your cancer doctor (oncologist) regularly for follow-up visits while you're taking hormone therapy for breast cancer. Your oncologist will ask about any side effects you're experiencing. Many side effects can be controlled.
Hormone therapy following surgery, radiation or chemotherapy has been shown to reduce the risk of breast cancer recurrence in people with early-stage hormone-sensitive breast cancers. It can also effectively reduce the risk of metastatic breast cancer growth and progression in people with hormone-sensitive tumors.
Depending on your circumstances, you may undergo tests to monitor your medical situation and watch for cancer recurrence or progression while you're taking hormone therapy. Results of these tests can give your doctor an idea of how you're responding to hormone therapy, and your therapy may be adjusted accordingly.
Feb. 20, 2014
- Breast cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Sept. 19, 2013.
- Hormone therapy for breast cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Therapy/hormone-therapy-breast. Accessed Sept. 19, 2013.
- American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Alexandria, Va.: American Society of Clinical Oncology. http://www.asco.org/institute-quality/asco-clinical-practice-guideline-update-adjuvant-endocrine-therapy-women-hormone. Accessed Sept. 19, 2013.
- Fareston (prescribing information). Bridgewater, N.J.: ProStrakan Inc.; 2012. http://www.fareston.com. Accessed Sept. 19, 2013.
- Arimidex (prescribing information). Wilmington, Del.: AstraZeneca; 2013. http://www.arimidex.com. Accessed Sept. 19, 2013.
- Aromasin (prescribing information). New York, N.Y.: Pfizer Inc.; 2013. http://www.aromasin.com. Accessed Sept. 19, 2013.
- Faslodex (prescribing information). Wilmington, Del.: AstraZeneca; 2012. http://www.faslodex.com. Accessed Sept. 19, 2013.
- Zoladex (prescribing information). Wilmington, Del.: AstraZeneca; 2013. http://www.zoladex.com. Accessed Sept. 19, 2013.
- Femara (prescribing information). East Hanover, N.J.: Novartis Pharmaceuticals Corporation; 2011. http://www.femara.com. Accessed Sept. 19, 2013.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. Sept. 23, 2013.